VEREGEN® is a prescription medicine applied to the skin for the treatment of EGW. VEREGEN® should be used by adults 18 and over on the genitals and around the outside of the anus.
Photo for illustrative purposes only. Not actual patients.
For illustrative purposes only.
| * | VEREGEN® was studied in 2 clinical trials in which patients with EGW applied either VEREGEN® or a treatment without drug called a “placebo.” Patients applied VEREGEN® to EGW 3 times a day for up to 16 weeks or until all warts were gone. Complete clearance was seen in 53.6% of patients treated with VEREGEN®. VEREGEN® is not a cure for EGW. New warts may develop during or after the use of VEREGEN® that may need treatment. |
Week 1 (baseline)
Week 12
REVEAL ACTUAL PHOTOS
Male patient from clinical trial at baseline and at week 12 of therapy with VEREGEN® Ointment, 15%.
Individual results may vary.
Week 1 (baseline)
Week 16
REVEAL ACTUAL PHOTOS
Female patient from clinical trial at baseline and at week 16 of therapy with VEREGEN® Ointment, 15%.
Individual results may vary.
Week 1 (baseline)
Week 16
REVEAL ACTUAL PHOTOS
Male patient from clinical trial at baseline and at week 16 of therapy with VEREGEN® Ointment, 15%.
Individual results may vary.
Week 1 (baseline)
Week 16
REVEAL ACTUAL PHOTOS
Male patient from clinical trial at baseline and at week 16 of therapy with VEREGEN® Ointment, 15%.
Individual results may vary.
First and second sets of photos provided with permission from Silvio Tatti, MD, PhD, First Chair Gynecology, Hospital de Clinicas, Buenos Aires, Argentina.
Third set of photos provided with permission from Eggert Stockfleth, Director of the Skin Cancer Center, University Hospital Charite, Berlin, Germany.
Fourth set of photos provided with permission from Theodore Rosen, MD, Professor of Dermatology, Baylor College of Medicine, Houston, Texas.
Use VEREGEN® only on the affected area, exactly as your doctor tells you.
WASH YOUR HANDS before and after you apply VEREGEN®
DAB A THIN LAYER of VEREGEN® on each wart with your fingers to make sure all warts are covered
APPLY VEREGEN® 3 times a day (morning, evening, before bedtime)
Photo for illustrative purposes only. Not actual patients.
Photo for illustrative purposes only. Not actual patients.
EGW=external genital and perianal warts
Do not use VEREGEN® (sinecatechins) Ointment, 15% if you are allergic to any ingredient in this product. Do not use VEREGEN® Ointment, 15% for warts in the vagina, cervix, or inside the anus. Avoid contact with your eyes, nostrils and mouth while ointment is on your finger(s).
Avoid use of VEREGEN® on open wounds. Do not expose skin that has been treated with VEREGEN® to the sunlight, sunlamps or tanning beds. Tell your doctor if you are using any other type of skin product on the area to be treated. Avoid sexual contact (genital, anal or oral) when VEREGEN® Ointment, 15% is on your genital or perianal skin. If you do choose to have sexual contact, you must wash off the ointment carefully before having protected sexual contact as the ointment may weaken condoms and vaginal diaphragms.
Be sure to tell the doctor if you have a weak immune system, if you are pregnant or nursing a baby, or if you have used VEREGEN® before. Avoid using this product in patients younger than 18 years of age or for longer than 16 weeks. If your warts do not go away or come back after treatment contact your doctor.
The most common side effects with VEREGEN® Ointment, 15% are local skin and application site reactions including (incidence ≥20%): redness, itching, burning, pain, sores, swelling, hard spots, and rash with blisters.
For more information, consult your healthcare professional.
Please see full Prescribing Information for VEREGEN®.
You are encouraged to report negative side effects of prescription drugs to the Food and Drug Administration (FDA). Please visit www.fda.gov/medwatch or call 1-800-FDA-1088.
VEREGEN® is indicated for the topical treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older.
Do not use VEREGEN® (sinecatechins) Ointment, 15% if you are allergic to any ingredient in this product. Do not use VEREGEN® Ointment, 15% for warts in the vagina, cervix, or inside the anus. Avoid contact with your eyes, nostrils and mouth while ointment is on your finger(s).
Avoid use of VEREGEN® on open wounds. Do not expose skin that has been treated with VEREGEN® to the sunlight, sunlamps or tanning beds. Tell your doctor if you are using any other type of skin product on the area to be treated. Avoid sexual contact (genital, anal or oral) when VEREGEN® Ointment, 15% is on your genital or perianal skin. If you do choose to have sexual contact, you must wash off the ointment carefully before having protected sexual contact as the ointment may weaken condoms and vaginal diaphragms.
Be sure to tell the doctor if you have a weak immune system, if you are pregnant or nursing a baby, or if you have used VEREGEN® before. Avoid using this product in patients younger than 18 years of age or for longer than 16 weeks. If your warts do not go away or come back after treatment contact your doctor.
The most common side effects with VEREGEN® Ointment, 15% are local skin and application site reactions including (incidence ≥20%): redness, itching, burning, pain, sores, swelling, hard spots, and rash with blisters.
For more information, consult your healthcare professional.
Please see full Prescribing Information for VEREGEN®.
You are encouraged to report negative side effects of prescription drugs to the Food and Drug Administration (FDA). Please visit www.fda.gov/medwatch or call 1-800-FDA-1088.
VEREGEN® is indicated for the topical treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older.
This section includes technical information. If you're a US healthcare provider, click "Continue." Otherwise, click "Return" to keep reading the patient site.
ANI Pharmaceuticals is not responsible for the privacy policy, the content, or the accuracy of any websites accessed through a link on the veregen.com site. A link to other websites does not constitute an endorsement of ANI Pharmaceuticals or the linked site, its products, or services.
The browser window or tab for veregen.com will remain open. To return to veregen.com at any time, close this tab or window.
Photo provided with permission from Silvio Tatti, MD, PhD, First Chair Gynecology, Hospital de Clinicas, Buenos Aires, Argentina.
Photo provided with permission from Silvio Tatti, MD, PhD, First Chair Gynecology, Hospital de Clinicas, Buenos Aires, Argentina.
Proto provided with permission from Eggert Stockfleth, Director of the Skin Cancer Center, University Hospital Charite, Berlin, Germany.
Photo provided with permission from Theodore Rosen, MD, Professor of Dermatology, Baylor College of Medicine, Houston, Texas.
Photo provided with permission from Silvio Tatti, MD, PhD, First Chair Gynecology, Hospital de Clinicas, Buenos Aires, Argentina.
Photo provided with permission from Silvio Tatti, MD, PhD, First Chair Gynecology, Hospital de Clinicas, Buenos Aires, Argentina.
Proto provided with permission from Eggert Stockfleth, Director of the Skin Cancer Center, University Hospital Charite, Berlin, Germany.
Photo provided with permission from Theodore Rosen, MD, Professor of Dermatology, Baylor College of Medicine, Houston, Texas.